向PRMT1可以减少EGFR和KRAS突变肺癌的癌症持续性和瘤复发
Xiaoxiao Sun1, Karl Kumbier1, Savitha Gayathri1
1Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Cancer research communications
|December 19, 2024
概括
向蛋白质氨酸甲基转移酶1 (PRMT1) 有助于消除持久性肺癌细胞,改善了向EGFR或KRASG12C突变的治疗结果. 这一策略提高了治疗效率,并延迟了癌症复发.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 在治疗期间癌细胞的根除不完全导致疾病复发.
- 针对EGFR和KRASG12C等瘤驱动因素是肺癌治疗的关键策略.
- 癌细胞的持久性对实现持久的治疗反应构成重大挑战.
研究的目的:
- 为了确定使癌细胞在瘤基因向治疗期间持续存在的分子机制.
- 研究I型蛋白质氨酸甲基转移酶 (PRMT) 在癌细胞持久性中的作用.
- 评估PRMT1作为克服EGFR或KRASG12C突变肺癌抵抗性的治疗标.
主要方法:
- 使用EGFR和KRASG12C突变肺癌的细胞系和异种移植模型.
- 对PRMT1,PRMT4和PRMT6异型进行了淘汰实验.
- 与EGFR或KRASG12C抑制剂结合使用PRMT1抑制剂.
- 评估了癌细胞的持久性,再生和瘤回归.
主要成果:
- 抑制PRMT1,结合向抑制剂,降低了癌细胞的持久性和延迟了癌细胞的再生.
- 抑制PRMT4和PRMT6异型会增加癌细胞的持久性.
- 向PRMT1在肺癌模型中显示出更大的有效性,这些模型具有完整的5q31.1染色体区域.
结论:
- 在EGFR或KRASG12C向治疗中,PRMT1是使癌细胞持续存在的关键因素.
- 向PRMT1提供了一种新的策略,可以消除持久细胞并改善治疗结果.
- 染色体5q31.1的状态可以作为PRMT1向治疗有效性的预测生物标志物.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.6K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K